Stock Price Quote

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE312.00-14.4 (-4.41 %)
PREV CLOSE ( ) 326.40
OPEN PRICE ( ) 326.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 139636
TODAY'S LOW / HIGH ( )308.80 328.05
52 WK LOW / HIGH ( )270 404.6
NSE311.85-14.9 (-4.56 %)
PREV CLOSE( ) 326.75
OPEN PRICE ( ) 326.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 311.85 (56)
VOLUME 4326450
TODAY'S LOW / HIGH( ) 308.45 328.40
52 WK LOW / HIGH ( )269.55 404.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

24Apr Biocon gets nod to raise Rs 4,500 crore
Biocon has received approval for raising of funds by way of issuance any..
23Apr Biocon raises Rs 600 crore through com
Biocon has raised Rs 600 crore through Commercial Papers (CPs) on privat..
23Apr Biocon trades higher on raising Rs 600
Biocon is currently trading at Rs 334.45, up by 0.50 points or 0.15% fro..
23Apr Allotment of Equity Shares
Inter-alia, considered and approved the following: 1. Fund Raising:- R..
23Apr Notice of Postal Ballot
Inter-alia, considered and approved the following: 1. Fund Raising:- R..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit58401193
Gross Profit 6039 1503
Operating Profit 9554557
Net Sales 562821273

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

TTK Healthcare (BSE)
peergroup  1233.80 (0.44%)
M.Cap ( in Cr)1743.40
Jagsonpal Pharma (BSE)
peergroup  243.55 (1.82%)
M.Cap ( in Cr)1618.11
Alivus Life Sciences (BSE)
peergroup  1034.35 (0.39%)
M.Cap ( in Cr)12688.71
Oxygenta Pharma (BSE)
peergroup  85.05 (4.70%)
M.Cap ( in Cr)314.36
Bafna Pharma (BSE)
peergroup  79.74 (4.99%)
M.Cap ( in Cr)188.64

Shareholding Pattern

MUTUAL FUNDS/UTI 8.77%
PROMOTERS 60.64%
FI/BANKS/INSURANCE 6.55%
NON-INSTITUTION 17.97%
GOVERNMENT 0%
FII 0%

About Biocon Ltd.

Biocon Ltd. was incorporated in the year 1978. Its today's share price is 312. Its current market capitalisation stands at Rs 37458.72 Cr. In the latest quarter, company has reported Gross Sales of Rs. 21273 Cr and Total Income of Rs.23673 Cr. The company's management includes Atul Dhawan, Nicholas Robert Haggar, Rekha Mehrotra Menon, Naina Lal Kidwai, Bobby Kanubhai Parikh, Eric Vivek Mazumdar, Ravi Rasendra Mazumdar, Siddharth Mittal, Kiran Mazumdar-Shaw.

It is listed on the BSE with a BSE Code of 532523 , NSE with an NSE Symbol of BIOCON and ISIN of INE376G01013. It's Registered office is at 20th Km,Hosur Road,Electronic CityBengaluru-560100, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, SR Batliboi & Associates, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.